PP
GLUE icon

Paladin Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Paladin Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.2K Hold
1,000
– – 0.02% 103
2026
Q1 		$16.4K Hold
1,000
– – 0.01% 115
2025
Q4 		$15.7K Buy
+1,000
New +$13.5K 0.01% 120

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paladin Partners's GLUE Position: Q2 2026 in Review

Paladin Partners held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 1,000 shares worth $24.2K. The position accounts for 0.02% of the portfolio, ranked #103.

Paladin Partners first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Paladin Partners held 1,000 shares of Monte Rosa Therapeutics worth $24.2K as of Q2 2026.
  • Paladin Partners left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up 0.02% of Paladin Partners's portfolio in Q2 2026, its #103 holding.
  • Paladin Partners first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.